Analyst Price Target is $34.00
▲ +86.10% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Calliditas Therapeutics AB (publ) in the last 3 months. The average price target is $34.00, with a high forecast of $50.00 and a low forecast of $18.00. The average price target represents a 86.10% upside from the last price of $18.27.
Current Consensus is
Moderate Buy
The current consensus among 2 polled investment analysts is to moderate buy stock in Calliditas Therapeutics AB (publ). This Moderate Buy consensus rating has held steady for over two years.
Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was founded in 2004 and is headquartered in Stockholm, Sweden.
Read More
